Hong Kong stock market anomaly | Sierin Pharmaceuticals (00460.HK) rose by more than 3%, with expected mid-term net profit not less than 50 million RMB, achieving high growth in medical beauty business.

According to the Intelligence Finance APP, Four Seasons Medicine (00460.HK) has risen by more than 3%, as of the time of writing, up by 3.2%, to 77.5 Hong Kong dollars, with a trading volume of 2.35 billion Hong Kong dollars.